

REMARKS

In the Office Action of August 14, 2007, the Examiner rejected claims 4-7 and 9-10 under 35 U.S.C. § 112, first paragraph, for lack of enablement. The Examiner has objected to the term "vaccine" in the absence of challenge studies being included in the specification.

Applicants have amended the claims to be directed to immunogenic compositions. Accordingly, it is believed that claims 4-7, 9 and 10, as presently amended, are in condition for allowance. Claims 1 and 8 have previously been viewed as allowable by the Examiner.

Although it is believed all claims are in condition for allowance, should the Examiner wish to discuss this case she is invited to telephone Applicants' attorney at the number below.

Applicants do not believe that any other fee is due in connection with this filing. If, however, Applicants do owe any such fee(s), the Commissioner is hereby authorized to charge the fee(s) to **Deposit Account No. 02-2334**. In addition, if there is ever any other fee deficiency or overpayment under 37 C.F.R. §1.16 or 1.17 in connection with this patent application, the Commissioner is hereby authorized to charge such deficiency or overpayment to **Deposit Account No. 02-2334**.


USSN: 10/527,767

Attorney Docket: 2002.016 US

Response to Office Action of August 14, 2007

Applicants submit that this application is in condition for allowance, and request that it be allowed. The Examiner is requested to call the Undersigned if any issues arise that can be addressed over the phone to expedite examination of this application.

Respectfully submitted,



William M. Blackstone, PTO Reg. No. 29772
Chief Patent Counsel
Intervet Inc.
Patent Department
P.O. Box 318
29160 Intervet Lane
Millsboro, DE 19966
(302) 934-4317 (tel)
(302) 934-4305 (fax)

WMB:dap